Curis, Inc.
A clinical-stage biotechnology company in Lexington, Massachusetts, developing emavusertib, an oral pill for blood cancers like primary central nervous system lymphoma and chronic lymphocytic leukemia. Formed in 2000 from the merger of three Boston-area biotech firms, its logo carries a musical fermata—a symbol that holds a note—reflecting its goal of prolonging life and curing cancer. Curis also helped develop Erivedge, an approved treatment for advanced basal cell carcinoma.
Bought 10.21M
Sold 2.97M
Sold 1.30M
Granted 675.0K · Bought 150.0K · Sold 875.0K
Granted 206.3K · Bought 115.9K
Granted 1.19M · Bought 45.0K · Sold 914.6K
Granted 172.5K · Sold 12.0K
Granted 133.8K
Granted 206.3K · Sold 23.1K
Granted 205.7K · Bought 10.0K · Sold 69.1K
Granted 49.7K · Sold 30.7K
Bought 30.0K
Granted 185.0K · Bought 51.6K · Sold 18.5K
Granted 208.7K · Sold 192.1K
Granted 425.0K · Sold 223.5K
Granted 185.0K · Sold 5.5K
Granted 185.0K · Sold 14.8K
Granted 20.0K
Granted 235.0K · Bought 16.8K · Sold 29.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Aurigene Discovery Technologies Ltd +2 co-filers10% owner · 1 transaction | — | 27.33Mas of Sep 2016 | — | 10.21M | — |
| Biotechnology Value Fund II LP +4 co-filersDirect Beneficial Owner · 3 transactions | — | 24.07Mas of Apr 2009 | — | — | 2.97M |
| Aldrich Richard +4 co-filers10% owner · 1 transaction | — | 13.80Mas of Apr 2008 | — | — | 1.30M |
| McNab James RDirector · 48 transactions | — | 2.05Mas of May 2017 | 675.0K | 150.0K | 875.0K |
| Fattaey Ali Ph.D.President & CEO, Director · 4 transactions | — | 322.1Kas of Jan 2018 | 206.3K | 115.9K | — |
| Passeri Daniel RDirector · 48 transactions | — | 211.8Kas of Jan 2016 | 1.19M | 45.0K | 914.6K |
| Tobin James RDirector · 9 transactions | — | 186.8Kas of May 2013 | 172.5K | — | 12.0K |
| Tuck DavidChief Medical Officer · 1 transaction | — | 169.4Kas of Jan 2018 | 133.8K | — | — |
| Dentzer James EPresident & CEO, Director · 10 transactions | — | 148.7K | 206.3K | — | 23.1K |
| Gray MichaelCFO · 13 transactions | — | 107.3Kas of Nov 2013 | 205.7K | 10.0K | 69.1K |
| Duvall DianthaCFO · 1 transaction | — | 77.7K | — | — | — |
| Hamdy Ahmed MDCMO · 1 transaction | — | 66.7K | — | — | — |
| Zung Jonathan B.CDO · 1 transaction | — | 66.7K | — | — | — |
| Bayh Susan BDirector · 6 transactions | — | 43.8Kas of Dec 2011 | 49.7K | — | 30.7K |
| Pienta KennethDirector · 2 transactions | — | 30.0Kas of Nov 2013 | — | 30.0K | — |
| Rubin MarcDirector · 5 transactions | — | 28.1K | 185.0K | 51.6K | 18.5K |
| Noel MarkVP, Tech Management · 17 transactions | — | 27.5Kas of May 2013 | 208.7K | — | 192.1K |
| Greenacre Martyn DDirector · 18 transactions | — | 26.1Kas of Jan 2019 | 425.0K | — | 223.5K |
| Martell RobertHead of Research & Development · 3 transactions | — | 23.0Kas of Jan 2019 | 185.0K | — | 5.5K |
| Kunkel Lori AnneDirector · 2 transactions | — | 22.2Kas of Jan 2019 | 185.0K | — | 14.8K |
| Davie Joseph MDirector · 2 transactions | — | 20.0Kas of Jun 2007 | 20.0K | — | — |
| Kaitin Kenneth IDirector · 13 transactions | — | 11.4K | 235.0K | 16.8K | 29.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +3.95M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.